Designing Chimeric Antigen Receptors for Myeloid Immune Cells

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cells are established cancer therapies.
• CAR myeloid cells offer a potential alternative for solid tumor treatment.
• Existing CAR myeloid strategies involve adapting T-cell CARs or designing myeloid-specific domains.

Purpose of the Study:

• To review the current preclinical and clinical research on CAR myeloid cell strategies.
• To compare different CAR myeloid receptor designs and their efficacy.
• To identify knowledge gaps and future directions for clinical translation.

Main Methods:

• Review of preclinical and clinical studies on CAR myeloid cells.
• Comparison of various CAR myeloid cell types (monocytes, macrophages, dendritic cells, neutrophils).
• Analysis of different CAR signaling domains (ITAM, TIR, MerTK) and functional additions (CD147, cytokines).

Main Results:

• Toll-interleukin-1 receptor (TIR) and MerTK signaling domains show potential for enhanced myeloid cell activation compared to ITAM-based receptors.
• CAR monocytes, macrophages, and dendritic cells are actively researched, with CAR-DCs explored for tumor vaccines.
• Strategies for CAR neutrophils, such as using undifferentiated progenitors, are being investigated to overcome their short lifespan.

Conclusions:

• CAR myeloid cells represent a promising area of cancer immunotherapy research.
• Optimizing CAR myeloid cell receptor design and cell type selection is crucial for efficacy.
• Further preclinical studies are needed to advance CAR myeloid therapies towards clinical application.